The oncology sweep returned one item from the drug approval feed, a supplemental approval for vemurafenib on 20 August, which changes nothing clinically. The enforcement feed was empty. As usual, the automated feeds do not reach ASCO, ESMO, NCCN or NCI guidance published as web documents, nor CDSCO notices, so an empty regulatory day reflects coverage rather than silence.
The substantive guidance is the American College of Gastroenterology's new clinical guideline on adenomatous colorectal polyposis syndromes, developed using GRADE methodology. It covers who should undergo risk assessment for a hereditary polyposis syndrome, the modality and timing of germline genetic testing, endoscopic and surgical risk mitigation, and the role of chemoprevention, with a focus on familial adenomatous polyposis and MUTYH-associated polyposis.
The part most relevant to an oncologist is the presymptomatic diagnosis pathway. These syndromes carry cancer risk across the colon, rectum, duodenum, ampulla and stomach, and the interventions that reduce mortality — timed colectomy, upper gastrointestinal surveillance, cascade testing of relatives — all depend on identifying the family before the index cancer, not after it.
In Indian practice the practical bottleneck is cascade testing. A germline pathogenic variant identified in one patient should trigger testing of first-degree relatives, and that referral is the step most often lost between the oncology clinic and the family. Where genetic counselling services are thin, the treating oncologist is the person who has to make it happen or it does not happen at all.
- Take a structured personal and family history for polyposis in every patient with multiple colorectal adenomas
- Arrange germline genetic testing where the phenotype suggests a syndrome, rather than deferring it indefinitely
- Remember the extracolonic risk — duodenum, ampulla and stomach need their own surveillance schedule
- Drive cascade testing of first-degree relatives yourself where genetic counselling access is limited
- Note the coverage gap: ASCO, ESMO, NCCN and CDSCO guidance do not reach this feed
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free